Gunnarsson Orvar, Basaria Shehzad, Gignac Gretchen A
Department of Medicine, Division of Hematology and Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104, USA.
Department of Medicine, Section of Men's Health, Aging and Metabolism, Brigham and Women's Hospital, Boston, MA 02115, USA.
Cancers (Basel). 2015 Apr 22;7(2):679-87. doi: 10.3390/cancers7020679.
Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with multiple metabolic complications, previously predominantly evaluated in the white population.
A chart-based retrospective review was conducted on black patients with PCa, considered for ADT, from September 2007 to July 2010. Baseline data were collected on body mass index (BMI), vitamin-D status, bone mineral density (BMD), dyslipidemia and diabetes. Overweight and obesity were classified as BMI ≥ 25 and BMI ≥ 30, respectively. Vitamin-D sufficiency was defined as levels ≥30 ng/mL, insufficiency as <30 ng/mL and deficiency as ≤20 ng/mL. Osteopenia was defined as T scores between -1 to -2.5 and osteoporosis when T scores ≤-2.5.
Of the initial cohort of 130 black men, 111 (85.4%) patients underwent ADT. At baseline, average BMI was 28.1 ± 5.9 with 43.3% of men being overweight and 30.8% obese. More than one-third of the patients had pre-existing dyslipidemia while 28.8% were diabetics. 50% were vitamin-D deficient while 41% had low bone mass.
Black men with PCa presenting for consideration of ADT have a high prevalence of existing metabolic risk factors. Close monitoring of this patient population is needed during ADT to prevent and treat metabolic complications.
前列腺癌（PCa）的雄激素剥夺疗法（ADT）与多种代谢并发症相关，此前主要在白人人群中进行评估。
对2007年9月至2010年7月间考虑接受ADT治疗的黑人前列腺癌患者进行基于病历的回顾性研究。收集了体重指数（BMI）、维生素D状态、骨密度（BMD）、血脂异常和糖尿病的基线数据。超重和肥胖分别定义为BMI≥25和BMI≥30。维生素D充足定义为水平≥30 ng/mL，不足定义为<30 ng/mL，缺乏定义为≤20 ng/mL。骨量减少定义为T值在-1至-2.5之间，骨质疏松定义为T值≤-2.5。
在最初的130名黑人男性队列中，111名（85.4%）患者接受了ADT治疗。基线时，平均BMI为28.1±5.9，43.3%的男性超重，30.8%肥胖。超过三分之一的患者已有血脂异常，28.8%为糖尿病患者。50%的患者维生素D缺乏，41%骨量低。
考虑接受ADT治疗的黑人前列腺癌男性患者中，现有代谢危险因素的患病率很高。在ADT治疗期间需要密切监测该患者群体，以预防和治疗代谢并发症。
